Shanghai RAAS(002252)2018-02-27 16:00Financial Performance - Total operating revenue for 2017 was CNY 1,927,748,425.11, a decrease of 17.13% compared to the previous year[5] - Net profit attributable to shareholders for 2017 was CNY 850,410,752.11, down 47.28% year-on-year[5] - Basic earnings per share decreased to CNY 0.17, a decline of 46.88% from CNY 0.32 in the previous year[5] - The weighted average return on net assets fell to 7.05%, a decrease of 7.11 percentage points compared to 14.16% in the previous year[5] Assets and Equity - Total assets increased by 9.30% to CNY 14,455,183,385.64 at the end of 2017[5] - Shareholders' equity attributable to the company rose by 6.56% to CNY 12,476,340,873.82[5] Revenue Decline Factors - The decline in revenue was primarily due to the suspension of production at subsidiary Zhengzhou Laisai for capacity expansion and technical upgrades[6][7] - The implementation of the "two-invoice system" in the pharmaceutical industry had a short-term impact on the company's revenue in 2017[7] - The company reported a significant decrease in fair value gains and investment income due to stock price fluctuations[7] Profit Forecast Alignment - The performance report aligns with the previously announced profit forecast, which estimated a net profit change of -39% to -49%[8]